Phase IIa Clinical trial
New indication and reformulation of an already approved and clinically available drug. The drug is administered as a pretreatment to the gold standard chemotherapy (R-CHOP) for first-line treatment of Diffuse Large B-Cell Lymphoma (DLBCL).
License and development agreement with Cadila Pharmaceuticals Ltd.
Highly bronchodilating substances with documented effect on transplanted human lung tissue from both normal and COPD patients.
Biomarkers for cardiovascular PET-imaging.
Technology platform developed by Respiratorius for smooth muscle cell tissue research.
Open for collaboration and further applications of RESP-HSAT.